Merck & Co., Inc., Kenilworth, NJ, USA is a global healthcare leader working to help the world be well. From developing new therapies that treat and prevent disease to helping people in need, we are committed to improving health and well-being around the world. The Merck Manual was first published in 1899 as a service to the community. The legacy of this great resource continues as the Merck Manual in the US and Canada and the MSD Manual outside of North America. Learn more about our commitment to Global Medical Knowledge.
AB - In this study, the ability of Apigenin, Berberine and Rutin to reduce cholesterol metabolism in human hepatoma cancer cell line (Hep G2) was determined. Cytotoxic assessment of Apigenin, Berberine and Rutin were performed by exposing the Hep G2 to Apigenin, Berberine and Rutin at concentrations ranging from to 1000 μg/mL for 24 h at 37°C and with 5% CO 2 atmosphere. The inhibition concentration 20 (IC20) of Apigenin, Berberine and Rutin were , 125 and 1000 μg/mL, respectively. The ability of reducing cholesterol metabolism effects of Apigenin, Berberine and Rutin on Hep G2 was carried out by seeding the cell in 6-well plates. In the treated groups, Hep G2 was treated with Apigenin, Berberine and Rutin (, and μg/mL, respectively) and exposed to 10 μL low density lipoprotein (LDL). In the normal control (NC) groups, Hep G2 was incubated with culture medium only. The cell was incubated and media was taken for analysis of Apo A1, LCAT, LDLR and FDFT1 by using kit. Rutin was able to lower down HMGR activity significantly (p